Last edition
News about "plozasiran hypertriglyceridemia treatment"
Arrowhead Pharmaceuticals Reports Long-Term Efficacy, Safety Data for Plozasiran
Arrowhead Pharmaceuticals reports long-term phase 2b data showing plozasiran reduces triglycerides by 83 percent in sHTG patients, with no pancreatitis events and sustained improvements in lipid markers and safety.
Plozasiran Hypertriglyceridemia Treatment | 30/03/2026 | By News Bureau | 167
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members